Leiomyosarcoma
Drug research and approvals for leiomyosarcoma: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 36 studies of leiomyosarcoma are recruiting on ClinicalTrials.gov, Health Canada has authorized 2 drug trials for it since 2013, and FDA has 1 approved and 0 open orphan designations naming it.
- Recruiting worldwide: 36
- Trials authorized in Canada: 2
- FDA orphan approvals: 1
- EU medicines: 0
- Doxorubicin Plus Dacarbazine Versus Doxorubicin Alone as First-Line Therapy for Metastatic or Recurrent Uterine…NCT07942168 · Phase 2 · Blokhin's Russian Cancer Research Center · starts Jan 24, 2023
- A Phase 1b, Open-Label Study Of REC-617, A Selective CDK7 Inhibitor, In Patients With Metastatic Or Unresectable…NCT07633756 · Phase 1 · M.D. Anderson Cancer Center · starts Oct 19, 2026
- Feasibility Study on the Effect of a Methionine-Reduced Diet on Serum Levels in Pts w/ Solid TumorsNCT07628634 · Early Phase 1 · University of California, Irvine · starts May 1, 2026
- A Study of Ivonescimab in People With LeiomyosarcomaNCT07516925 · Phase 2 · Memorial Sloan Kettering Cancer Center · starts Apr 1, 2026
- Ph 2 Elacestrant in ER Positive Uterine SarcomasNCT07467772 · Phase 2 · Dana-Farber Cancer Institute · starts Mar 25, 2026
- Precision Medicine Approaches for Neoadjuvant Therapy in High-risk Sarcoma PatientsNCT07432932 · Not reported · Royal Marsden NHS Foundation Trust · starts Nov 19, 2021
- Dose-escalated, Hypofractionated, Definitive Proton Radiotherapy for Patients With Inoperable Soft Tissue Sarcoma.NCT07173972 · Phase 2 · Oslo University Hospital · starts Jan 26, 2026
- Hypofractionated, 3-week, Preoperative Proton or X-ray Radiotherapy for Patients With Localized Soft Tissue SarcomaNCT07169344 · Phase 2 · Oslo University Hospital · starts Jan 26, 2026
- Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic LeiomyosarcomaNCT07125183 · Phase 2 · University of Colorado, Denver · starts Dec 1, 2026
Approved 1
- TrabectedinDNA inhibitor
Phase 3 4
- DoxorubicinDNA topoisomerase II alpha inhibitor
- DacarbazineDNA inhibitor
- IfosfamideDNA inhibitor
- CatequentinibVascular endothelial growth factor receptor 2 inhibitor
Phase 2 12 of 21
- GemcitabineRibonucleoside-diphosphate reductase RR1 inhibitor
- PazopanibMacrophage colony stimulating factor receptor inhibitor
- NivolumabProgrammed cell death protein 1 inhibitor
- LurbinectedinDNA negative modulator
- Unesbulin
- CarboplatinDNA inhibitor
- DinutuximabDisialoganglioside GD2 binding agent
- DocetaxelTubulin inhibitor
- TemozolomideDNA inhibitor
- BevacizumabVascular endothelial growth factor A inhibitor
- LetrozoleCytochrome P450 19A1 inhibitor
- Zoledronic acidFarnesyl diphosphate synthase inhibitor
Phase 1 or earlier 3
- SirolimusFK506-binding protein 1A inhibitor
- OlaratumabPlatelet-derived growth factor receptor alpha antagonist
- Nedisertib
How its trials ended
145 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 42 whose ending is known, 29% met their primary endpoint, 12% missed it and 60% stopped early.
- Ongoing5236%
- Completed, result not reported4128%
- Stopped: other or unclear1510%
- Met its primary endpoint128%
- Status unknown107%
- Missed its primary endpoint53%
- Stopped: enrollment or feasibility53%
- Stopped: sponsor or business decision53%
| Sep 26, 2023 | Docetaxel in previously treated subjects with leiomyosarcoma (ARGSARC): a randomized, double-blind, multi-center phase 3 trialAdi-peg 20 (pegargiminase) / Gemcitabine / Docetaxel | Polaris Pharmaceuticals, Inc. (A Subsidiary of Polaris Group) | Ongoing |
| May 26, 2022 | A phase 2/3 study to evaluate the efficacy and safety of unesbulin in unresectable or metastatic, relapsed or refractory leiomyosarcomaUnesbulin (PTC596)/ Dacarbazine | PTC Therapeutics | Closed |
| Date | Drug | Sponsor | Status |
|---|---|---|---|
| Oct 23, 2015 | YondelisFor the treatment of patients with unresectable or metastatic liposarcoma or leiomyosarcoma who received a prior anthracycline-containing… | Janssen Research & Development, LLC | Approved |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA